Oncology

Featured

FDA Approval

FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma

03/20/2026

Emily Estrada

Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.

Based on results from the SWOG...

03/20/2026

Oncology

Videos

Rethinking the Role of Second-Line Chemotherapy in Advanced Lung Cancer

03/20/2026

Daniel Rosas, MD, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.

Daniel Rosas, MD, discusses...

03/20/2026

Oncology

Videos

Clinical Differences Among Oral SERDs in HR-Positive, HER2-Negative Breast Cancer

03/20/2026

Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.

Sarah Premji, MD, discusses...

03/20/2026

Oncology

Videos

Biomarkers as the Foundation of Tumor-Agnostic Therapy

03/19/2026

Edward B. Garon, MD, MS

Edward Garon, MD, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.

Edward Garon, MD, discusses the...

03/19/2026

Oncology

Videos

Evolving Treatment Strategies for Patients With Relapsed or Refractory DLBCL

03/19/2026

Julio Chavez, MD

Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.

Julio Chavez, MD, reviews...

03/19/2026

Oncology

Videos

Immature Data Limit Conclusions on Continuous vs Fixed-Duration Frontline CLL Therapies

03/19/2026

Richard Furman, MD

Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.

Richard Furman, MD, discusses...

03/19/2026

Oncology

Videos

Evaluating ctDNA-Guided Therapy in Early-Stage Breast Cancer

03/19/2026

Adam Brufsky, MD, PhD

Adam Brufsky, MD, PhD, discusses the role of ctDNA and MRD in early-stage breast cancer.

Adam Brufsky, MD, PhD, discusses...

03/19/2026

Oncology

Videos

Refining HRD-Guided PARP Inhibitor Use in Advanced Ovarian Cancer

03/19/2026

Angeles Secord, MD, discusses the evolving role of HRD as a biomarker and the need for improved patient selection in advanced ovarian cancer.

Angeles Secord, MD, discusses...

03/19/2026

Oncology

Videos

Evaluating Adjuvant HAI Pump Therapy in Patients With Resected Colorectal Liver Metastases

03/19/2026

Midhun Malla, MD, MS

Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.

Midun Mala, MD, assesses the use...

03/19/2026

Oncology

Videos

Emerging Bladder Preservation Strategies for Patients With Muscle-Invasive Bladder Cancer

03/19/2026

Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.

Arnab Basu, MD, discusses...

03/19/2026

Oncology

Videos

Theranostics Advances in Solid Tumors

03/19/2026

Scott Tagawa, MD

Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.

Scott Tagawa, MD, discusses the...

03/19/2026

Oncology

Featured

Video Series on Updates in Clinical Development of Next-Generation Radioligand Therapies Streaming Now

Leading oncology experts discuss investigational somatostatin receptor–targeted radiopharmaceuticals and how emerging data may influence patient selection, treatment sequencing, and safety in neuroendocrine tumor care. Watch video 1 now!

Videos

Rethinking the Role of Second-Line Chemotherapy in Advanced Lung Cancer

03/20/2026

Daniel Rosas, MD, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.

Daniel Rosas, MD, discusses...

03/20/2026

Oncology

Videos

Clinical Differences Among Oral SERDs in HR-Positive, HER2-Negative Breast Cancer

03/20/2026

Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.

Sarah Premji, MD, discusses...

03/20/2026

Oncology

Videos

Biomarkers as the Foundation of Tumor-Agnostic Therapy

03/19/2026

Edward B. Garon, MD, MS

Edward Garon, MD, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.

Edward Garon, MD, discusses the...

03/19/2026

Oncology

Videos

Evolving Treatment Strategies for Patients With Relapsed or Refractory DLBCL

03/19/2026

Julio Chavez, MD

Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.

Julio Chavez, MD, reviews...

03/19/2026

Oncology

Videos

Immature Data Limit Conclusions on Continuous vs Fixed-Duration Frontline CLL Therapies

03/19/2026

Richard Furman, MD

Richard Furman, MD, discusses...

03/19/2026

Oncology

Videos

Evaluating ctDNA-Guided Therapy in Early-Stage Breast Cancer

03/19/2026

Adam Brufsky, MD, PhD

Adam Brufsky, MD, PhD, discusses the role of ctDNA and MRD in early-stage breast cancer.

Adam Brufsky, MD, PhD, discusses...

03/19/2026

Oncology

Videos

Refining HRD-Guided PARP Inhibitor Use in Advanced Ovarian Cancer

03/19/2026

Angeles Secord, MD, discusses the evolving role of HRD as a biomarker and the need for improved patient selection in advanced ovarian cancer.

Angeles Secord, MD, discusses...

03/19/2026

Oncology

Videos

Evaluating Adjuvant HAI Pump Therapy in Patients With Resected Colorectal Liver Metastases

03/19/2026

Midhun Malla, MD, MS

Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.

Midun Mala, MD, assesses the use...

03/19/2026

Oncology

Videos

Emerging Bladder Preservation Strategies for Patients With Muscle-Invasive Bladder Cancer

03/19/2026

Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.

Arnab Basu, MD, discusses...

03/19/2026

Oncology

Videos

Theranostics Advances in Solid Tumors

03/19/2026

Scott Tagawa, MD

Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.

Scott Tagawa, MD, discusses the...

03/19/2026

Oncology

Insights From the ASCO Annual Meeting

Conference Coverage

Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis

09/03/2025

Raajit Rampal, MD, PhD

Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.

Raajit Rampal, MD, PhD shares...

09/03/2025

Oncology

Videos

Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer

08/21/2025

John Strickler, MD

John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.

John Strickler, MD, discusses...

08/21/2025

Oncology

Conference Coverage

Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML

08/20/2025

Amer Zeidan, MBBS

Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.

Amer Zeidan, MBBS, MHS, shares...

08/20/2025

Oncology

Conference Coverage

Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma

08/12/2025

Meghan Mooradian, MD

Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.

Meghan Mooradian, MD, discusses...

08/12/2025

Oncology

Conference Coverage

Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer

08/12/2025

Nicholas James, MD

Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...

Nick James, MD, PhD, discusses...

08/12/2025

Oncology

Conference Coverage

Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma

08/05/2025

Stephen Bagley, MD

Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.

Stephen Bagley, MD, discusses...

08/05/2025

Oncology

Conference Coverage

First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases

07/24/2025

Zeynep Eroglu, MD

Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...

Zeynep Eroglu, MD, discusses...

07/24/2025

Oncology

Conference Coverage

BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer

07/24/2025

Herbert Loong, MD

Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.

Herbert Loong, MD, discusses...

07/24/2025

Oncology

Conference Coverage

Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma

07/24/2025

Georgina Long, MBBS, PhD

Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...

Georgina Long, MD, PhD,...

07/24/2025

Oncology

Conference Coverage

Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma

07/24/2025

Alexander Van Akkooi, MD, PhD

Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.

Alexander Van Akkooi, MD, PhD,...

07/24/2025

Oncology

Insights From the ESMO Congress

Videos

Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer

12/02/2025

Stephen J. Freedland, MD

Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.

Stephen Freedland, MD, discusses...

12/02/2025

Oncology

Videos

Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer

12/02/2025

Brian M. Slomovitz, MD, MS

Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

Brian Slomovitz, MD, discusses...

12/02/2025

Oncology

Videos

Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC

12/02/2025

Pasi Jänne, MD, PhD

Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.

Pasi Jänne, MD, PhD, discusses...

12/02/2025

Oncology

Videos

Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer

12/02/2025

David Goldstein, MD

David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.

David Goldstein, MD, discusses...

12/02/2025

Oncology

Videos

Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer

11/13/2025

Sara Lonardi, MD

Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.

Sara Lonardi, MD, shares updated...

11/13/2025

Oncology

Videos

First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC

11/13/2025

Sanjay Popat, MD

Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.

Sanjay Popat, MD, PhD, discusses...

11/13/2025

Oncology

Videos

Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma

11/10/2025

Janice Mehnert, MD

Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.

Janice Mehnert, MD, discusses...

11/10/2025

Oncology

Videos

MCED Blood Test Detects Cancer Early With High Accuracy

11/10/2025

Nima Nabavizadeh, MD

Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.

Nima Nabavizadeh, MD, discusses...

11/10/2025

Oncology

Videos

Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer

11/10/2025

Maria De Santis, MD

Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.

Maria De Santis, MD, discusses...

11/10/2025

Oncology

Videos

Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma

11/10/2025

Dean Fennell, MD, PhD

Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.

Dean Fennell, MD, PhD, discusses...

11/10/2025

Oncology

Live Meetings

Recent News

FDA Approval

FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma

03/20/2026

Emily Estrada

Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.

Based on results from the SWOG...

03/20/2026

Oncology

News

Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer

03/18/2026

Emily Estrada

According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.

According to a comparative...

03/18/2026

Oncology

News

Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma

03/11/2026

Stephanie Holland

Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...

Interim results from the phase 3...

03/11/2026

Oncology

News

Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma

03/11/2026

Stephanie Holland

Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.

Interim results from the phase 3...

03/11/2026

Oncology

News

FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer

03/11/2026

Stephanie Holland

Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.

Based on results from the OSPREY...

03/11/2026

Radiopharmaceutical Education Institute

FDA Alerts

Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial

03/11/2026

Stephanie Holland

Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.

Based on emerging safety data...

03/11/2026

Oncology

News

Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor

03/11/2026

Stephanie Holland

Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.

Updated safety results from the...

03/11/2026

Oncology

News

Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma

03/05/2026

Stephanie Holland

Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.

Results from the phase 3 C-POST...

03/05/2026

Oncology

FDA Approval

FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma

03/05/2026

Emily Estrada

Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.

Based on results from the phase...

03/05/2026

Oncology

News

Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer

03/04/2026

Emily Estrada

Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.

Results from the SWOG S162 study...

03/04/2026

Oncology